ClinicalTrials.gg
CompletedNCT05896748Updated Nov 26, 2024Results posted

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

A Phase 3 interventional study of Cabotegravir - Injectable Suspension (CAB LA) and Rilpivirine - Injectable Suspension (RPV LA) in Human Immunodeficiency Virus Type 1 (HIV-1), sponsored by ViiV Healthcare. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2022, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the anterior abdominal wall SC tissue compared with IM administration in the gluteus medius muscle in adult participants living with HIV-1 infection in the FLAIR study (NCT02938520).

02

Conditions studied

  • Human Immunodeficiency Virus Type 1 (HIV-1)

Browse trials for

Keywords

  • Antiretroviral agent
  • Rilpivirine
  • Cabotegravir
  • FLAIR
  • Human immunodeficiency virus
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 94 is close to the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed (FLAIR and Sub-study specific informed consent)
  • Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of 12 months while on the FLAIR study. Any disruptions in dosing during FLAIR must be discussed with the Medical Monitor for a final determination of eligibility into the sub-study.
  • Plasma -1 RNA \<50 c/mL at Sub-Study Screening.
  • History of Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination (or booster dosing) is allowed prior to sub study screening and will be allowed during the conduct of the sub-study as long as the vaccine (or boosters) are not administered within 14 days of virologic load (VL) assessments.
  • HIV-1 infected antiretroviral therapy (ART)-naive men or women aged 18 years or greater at the time of signing the informed consent.
  • HIV-1 infection as documented by Screening plasma HIV-1 RNA >=1000 cubic (c)/mL
  • Antiretroviral-naive (less than or equal to (\<=10) days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection). Any previous exposure to an HIV integrase inhibitor or non-nucleoside reverse transcriptase inhibitor will be exclusionary
  • Female Participants: A female participant is eligible to participate if she is not pregnant at Screening and first day of Induction Phase (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies

    1. Non- defined as:

      • Pre-menopausal females with one of the following:
      • Documented tubal ligation;
      • Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion;
      • Hysterectomy; Documented Bilateral Oophorectomy;
      • defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.
    2. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, and for at least 30 days after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV LA.
  • The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception.
  • All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (example [e.g.,] male condom) and on the risk of HIV transmission to an uninfected partner.
  • In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • More than 1 plasma -1 RNA measurement 50 c/mL to \<200 c/mL (virologic blip) within 24 weeks prior to sub-study Screening visit that was investigated and found NOT to be associated with alternative causes including recent vaccinations received within 4 weeks of the viral blip or NOT associated with intercurrent illness that developed within 2-4 weeks of the viral blip.
  • All viral blips that occurred within 24 weeks prior to screening should be discussed with the Medical Monitor to assess whether such a participant can enroll into the sub-study.
  • Any Suspected Virologic Failure (HIV-RNA 200 c/mL) as defined during FLAIR study.
  • Participants planning to require oral bridging during participation in the FLAIR sub study.
  • The participant has a tattoo or any dermatological condition overlying the abdominal or gluteal regions which may interfere with interpretation of injection site reactions.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
  • Any woman of who is pregnant at screening will be excluded from entering the sub-study.
  • Any women of childbearing potential who gets pregnant while on the sub-study will have to be withdrawn from the sub-study but will be allowed to transition back to the parent FLAIR study if a pregnancy specific Form (ICF) is signed, and commercial access is not available at the time of pregnancy
  • Women who are pregnant, breastfeeding, or plan to become pregnant or breastfeed during the study.
  • Any evidence at Screening of an active Centers for Disease and Prevention Control (CDC) Stage 3 disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy or historic or current cluster of differentiation 4+ (CD4+) cell count \<200 cells/ cubic millimeter (mm\^3) are not exclusionary.
  • Participants with known moderate to severe hepatic impairment.
  • Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment.
  • Participant who, in the investigator's judgment, poses a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • The participant has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
  • Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti HBc), Hepatitis B surface antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows:

    • Participants positive for HBsAg are excluded;
    • Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.
  • Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who are anticipated to require HCV treatment prior to Week 48 of the Maintenance Phase must be excluded. HCV treatment on study may be permitted post Week 48, following consultation with the Medical Monitor. Participants with HCV co-infection will be allowed entry into Phase 3 studies if:

    • Liver enzymes meet entry criteria;
    • HCV Disease has undergone appropriate work-up, HCV is not advanced, and will not require treatment prior to the Week 48 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver , fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.
    • In the event that recent biopsy or imaging data is not available or is inconclusive, the Fib-4 score will be used to verify eligibility.
    • A Fib-4 score > 3.25 is exclusionary;
    • Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 Score Formula: (Age * )/ ( * [square root of ALT]).
  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or pancreatitis.
  • All participants will be screened for syphilis (rapid plasma reagin [RPR]). Participants with untreated syphilis infection, defined as a positive RPR without clear documentation of treatment, are excluded. Participants with a positive RPR test who have not been treated may be rescreened at least 30 days after completion of antibiotic treatment for syphilis.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study Medical Monitor for inclusion of the participant prior to enrollment.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the participant unable to receive study medication.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
  • Current or anticipated need for chronic anti-coagulation.
  • ALT >=3 times upper limit normal ().
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
  • Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of product (IP).
  • Treatment with any of the following agents within 28 days of Screening:

    • radiation therapy;
    • cytotoxic chemotherapeutic agents;
    • tuberculosis (TB) therapy, with the exception of treatment of latent TB with isoniazid;
    • Immunomodulators that alter immune responses (such as chronic systemic , interleukins, or interferons).
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of the first dose of IP.
  • Use of medications which are associated with Torsades de Pointes
  • Any evidence of primary resistance to non-nuclease reverse transcriptase inhibitors (NNRTIs) (except for K103N which is allowed), or any known resistance to Integrase inhibitors from historical resistance test results.
  • Participants who are human leukocyte antigen (HLA)-B*5701 positive and are unable to use an NRTI backbone that does not contain abacavir (participants who are HLA-B*5701 positive may be enrolled if they use a nuclease reverse transcriptase inhibitors (NRTI) backbone that does not contain abacavir; HLA-B*5701 positive participants may be excluded from the study if local provision of an alternate NRTI backbone is not possible).
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening Phase to verify a result.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the participant's participation in the study of an investigational compound.
  • Participant has estimated \<50 mL/minute (min)/1.73 meter square (m\^2) via the Chronic Kidney Disease Epidemiology Collaboration () equation.
  • Participants who are currently participating in or anticipate to be selected for any other interventional study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg

    Participants received an intramuscular (IM) injection of CAB LA 400 mg and RPV LA 600 mg on week -4 during the Screening phase. Participants then received a sub-cutaneous (SC) injection of CAB LA 400 mg + RPV LA 600 mg on Day 1 of Week 1, Week 4 and Week 8 (once in every 4 weeks (Q4W)) for a total of 12 weeks during the SC abdominal Injection Phase. 4 weeks later, participants returned to the clinic for an IM gluteal injection (at Week 12) of CAB LA 400 mg + RPV LA 600 mg during the Return to Gluteal Injection Phase and subsequent gluteal injection occurred after Q4W at Week 16.

    Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)

Interventions

  • It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.

  • It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

06

What researchers measure

Primary outcomes

  1. Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC injections; and Week 12 for Return to IM gluteal injection

  2. Ctau of RPV LA 600 mg Following Administration of CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection

  3. Maximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection

  4. Cmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening Week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection

  5. Area Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12, for Return to IM gluteal injection

  6. AUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA

    Blood samples were collected at indicated time points for PK analysis.

    Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection

Secondary outcomes

  1. Number of Participants With Injection Site Reactions (ISRs) and by Maximum Severity - SC Injection Phase

    Severity of ISRs was analyzed using division of acquired immunodeficiency syndrome (DAIDS) grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition.

    Time frame: From Day 1 Up to Week 12

  2. Number of Participants With Adverse Events of Special Interest (AESI) Based on Maximum Severity Grade - SC Injection Phase

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AESI was analyzed using DAIDS grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition. AESI assessed were Depression, Anxiety, Impact on creatinine, Hyperglycaemia.

    Time frame: From Day 1 Up to Week 12

  3. Number of Participants Who Discontinue Treatment Due to ISRs and AESIs - SC Injection Phase

    Time frame: From Day 1 Up to Week 12

  4. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From the Last IM Gluteal Injection in Screening Phase to the End of the SC Injection Phase

    SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs.

    Time frame: From Week -4 Up to Week 12

  5. Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Creatine Phosphokinase

    Blood samples were collected as assessed by protocol, at specific time points for the analysis of clinical chemistry parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  6. Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine, Total Bilirubin

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  7. Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Glucose, Potassium, Sodium, Blood Urea Nitrogen, Carbon Dioxide, Chloride, Phosphate

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  8. Change From Baseline in Chemistry Parameter Following Administration of SC Injection: Albumin

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  9. Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Lipase

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  10. Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine Clearance

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  11. Change From Baseline in Fasting Lipid Panels Following Administration of SC Injection: Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Triglycerides

    Time frame: Baseline (screening Week -4), and CFB at Week 12

  12. Change From Baseline in Hematology Parameters Following Administration of SC Injection: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelet Count

    Blood samples were collected as assessed by protocol, at specific time points for the analysis of hematology parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  13. Change From Baseline in Hematology Parameter Following Administration of SC Injection: Red Blood Cell (RBC) Count

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  14. Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hemoglobin

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  15. Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hematocrit

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  16. Change From Baseline in Hematology Parameter Following Administration of SC Injection: Mean Corpuscular Volume

    Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12

  17. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (c/mL) Using the Food and Drug Administration (FDA) Snapshot Algorithm - SC Injection Phase

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12

  18. Percentage of Participants With Plasma HIV RNA Greater Than Equal to (>=) 50 c/mL as Per FDA Snapshot Algorithm - SC Injection Phase

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12

  19. Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. CVF was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.

    Time frame: From Day 1 Up to Week 12

  20. Number of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase

    Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent phenotypic resistance were reported.

    Time frame: From Day 1 Up to Week 12

  21. Number of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase

    Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent genotypic resistance were reported.

    Time frame: From Day 1 Up to Week 12

  22. Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week-3 - Screening/IM Gluteal Injection Phase

    A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Week -3 (Baseline)

  23. Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week 1 - SC Injection Phase

    A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Day 1

  24. Number of Participants With Post-injection Pain Assessment Using NRS on Week 9- SC Injection Phase

    A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Week 9

  25. Number of Participants With Post-injection Pain Assessment Using NRS on Week 13- Return to IM Gluteal Injection Phase

    A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Week 13

  26. HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase

    HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

    Time frame: Week -3 (Baseline)

  27. HIVTSQs Total Score -SC Injection Phase

    HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

    Time frame: At Week 9

  28. HIVTSQs Total Score -Return to IM Gluteal Injection Phase

    HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

    Time frame: At Week 17

  29. Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points -SC Injection Phase

    HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

    Time frame: Baseline (Week -3) and up to Week 9

  30. Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

    HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

    Time frame: Baseline (Week -3) and up to Week 17

  31. Change From Study Week 9 to Study Week 17 in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

    HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

    Time frame: Week 9 and Week 17

  32. HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Individual Item Score at Indicated Time Points -SC Injection Phase

    HIVTSQc is a 12-item questionnaire to measure treatment satisfaction in HIV participants. Individual items were rated as +3 (much more satisfied) to -3(much less satisfied). Higher the score, greater the improvement in satisfaction with each aspect of treatment and lower the score, greater the deterioration in satisfaction with each aspect of treatment. Data was reported for each treatment satisfaction item based on the following items:Item 1=satisfaction with current treatment,Item2=level of HIV control based on treatment,Item3=any side effects of present treatment,Item4=demands made by current treatment,Item 5=convenience in finding treatment,Item 6=flexibility in finding treatment,Item 7=understanding HIV,Item 8=extent to which the treatment fits in with lifestyle,Item 9=recommendation of present treatment to someone else,Item 10=continuation with present form of treatment,Item 11=easy or difficult treatment,Item 12=amount of discomfort/pain involved with present form of treatment.

    Time frame: From Week -4 up to Week 9

  33. HIVTSQc Total Score at Indicated Time Points -SC Injection Phase

    HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.

    Time frame: From Week -4 up to Week 9

  34. Perception of Injection (PIN) Questionnaire in Domain Scores and Individual Item Scores- Screening/IM Gluteal Injection Phase

    The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: At Week -3 (Baseline)

  35. PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase

    The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: At Week 1 and Week 9

  36. PIN Questionnaire in Domain Scores and Individual Item Scores - Return to IM Gluteal Injection Phase

    The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: At Week 13

  37. Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase

    The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Change from Baseline (Week -3) at Week 1 and Week 9

  38. Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

    The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

    Time frame: Change from Baseline (Week -3) at Week 13

  39. Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 9 - SC Injection Phase

    A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.

    Time frame: Up to Week 9

  40. Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 17 - Return to IM Gluteal Injection Phase

    A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.

    Time frame: Up to Week 17

07

Results

Posted Nov 26, 2024

Participant flow

Screening Phase (Week -4 up to Day 1)
Participant flow — Screening Phase (Week -4 up to Day 1)
MilestoneCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Started94
Completed93
Not completed1
Withdrew: Passed away due to unknown reasons1
SC Injection Phase (Day 1 up to Week 12)
Participant flow — SC Injection Phase (Day 1 up to Week 12)
MilestoneCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Started93
Completed87
Not completed6
Withdrew: Adverse event2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject3
Return to IM Glu Inj Phase(Week12-Week20
Participant flow — Return to IM Glu Inj Phase(Week12-Week20
MilestoneCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Started87
Completed86
Not completed1
Withdrew: Protocol violation1

Outcome measures

PrimaryConcentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening Week-4; Day 1, Week 4, Week 8 for SC injections; and Week 12 for Return to IM gluteal injection
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA
microgram per milliliter (µg/mL)CAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA2.759 ± 36.642.670 ± 37.022.607 ± 39.002.632 ± 38.872.797 ± 36.18
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.948 · 90% CI 0.901 to 0.998
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.935 · 90% CI 0.877 to 0.995
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.934 · 90% CI 0.872 to 1.000
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.999 · 90% CI 0.943 to 1.059
PrimaryCtau of RPV LA 600 mg Following Administration of CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Ctau of RPV LA 600 mg Following Administration of CAB LA + RPV LA
Nanograms per milliliter (ng/mL)CAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
Ctau of RPV LA 600 mg Following Administration of CAB LA + RPV LA137.021 ± 38.51138.611 ± 36.43135.620 ± 35.55128.590 ± 39.71139.879 ± 43.06
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 1.002 · 90% CI 0.952 to 1.056
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.961 · 90% CI 0.921 to 1.002
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.928 · 90% CI 0.885 to 0.973
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 1.003 · 90% CI 0.955 to 1.053
PrimaryMaximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection
Reported as:
Geometric mean · µg/mL
Maximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA
µg/mLCAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
Maximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA3.545 ± 34.773.316 ± 35.223.165 ± 36.773.215 ± 34.563.529 ± 37.05
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.942 · 90% CI 0.897 to 0.990
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.911 · 90% CI 0.860 to 0.965
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.910 · 90% CI 0.857 to 0.966
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 1.003 · 90% CI 0.938 to 1.074
PrimaryCmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening Week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection
Reported as:
Geometric mean · ng/mL
Cmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA
ng/mLCAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
Cmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA162.287 ± 35.73152.614 ± 36.56148.051 ± 35.27149.145 ± 36.91154.659 ± 36.38
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.938 · 90% CI 0.895 to 0.982
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.918 · 90% CI 0.876 to 0.963
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.905 · 90% CI 0.861 to 0.952
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.937 · 90% CI 0.891 to 0.986
PrimaryArea Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12, for Return to IM gluteal injection
Reported as:
Geometric mean · hour microgram per milliliter (h*µg/mL)
Area Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA
hour microgram per milliliter (h*µg/mL)CAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
Area Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA2051.172 ± 34.311997.801 ± 33.941943.596 ± 35.251943.787 ± 35.532155.520 ± 32.71
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.944 · 90% CI 0.906 to 0.983
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.944 · 90% CI 0.895 to 0.995
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.933 · 90% CI 0.876 to 0.994
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 1.040 · 90% CI 0.979 to 1.105
PrimaryAUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA

Blood samples were collected at indicated time points for PK analysis.

Time frame:
At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection
Reported as:
Geometric mean · h*µg/mL
AUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA
h*µg/mLCAB+RPV Screening Gluteal InjectionCAB+RPV First Sub-Cutaneous (SC) InjectionCAB+RPV Second SC InjectionCAB+RPV Last SC InjectionCAB+RPV Return to Intramuscular (IM) Gluteal Injection
AUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA98003.488 ± 34.3198801.696 ± 35.3295743.414 ± 34.5693248.069 ± 34.85100006.767 ± 34.78
Statistical analysis
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV First Sub-Cutaneous (SC) Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.966 · 90% CI 0.932 to 1.002
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Second SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.955 · 90% CI 0.922 to 0.989
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Last SC Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 0.948 · 90% CI 0.907 to 0.991
  • CAB+RPV Screening Gluteal Injection vs CAB+RPV Return to Intramuscular (IM) Gluteal Injection · Mixed effect analysisofcovariance(ANCOVA · Ratio of geometric least square mean: 1.014 · 90% CI 0.972 to 1.058
SecondaryNumber of Participants With Injection Site Reactions (ISRs) and by Maximum Severity - SC Injection Phase

Severity of ISRs was analyzed using division of acquired immunodeficiency syndrome (DAIDS) grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition.

Time frame:
From Day 1 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions (ISRs) and by Maximum Severity - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
ISRs85
Mild or Grade 1 ISRs43
Moderate or Grade 2 ISRs36
Severe or Grade 3 ISRs6
Potentially Life-Threatening or Grade 4 ISRs0
Death or Grade 5 ISRs0
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI) Based on Maximum Severity Grade - SC Injection Phase

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AESI was analyzed using DAIDS grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition. AESI assessed were Depression, Anxiety, Impact on creatinine, Hyperglycaemia.

Time frame:
From Day 1 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI) Based on Maximum Severity Grade - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Any Depression1
Mild or Grade 1 Depression0
Moderate or Grade 2 Depression1
Severe or Grade 3 Depression0
Potentially Life-Threatening or Grade 4 Depression0
Death or Grade 5 Depression0
Any Anxiety1
Mild or Grade 1 Anxiety1
Moderate or Grade 2 Anxiety0
Severe or Grade 3 Anxiety0
Potentially Life-Threatening or Grade 4 Anxiety0
Death or Grade 5 Anxiety0
Any Impact on Creatinine1
Mild or Grade 1 Impact on Creatinine1
Moderate or Grade 2 Impact on Creatinine0
Severe or Grade 3 Impact on Creatinine0
Potentially Life-Threatening or Grade 4 Impact on Creatinine0
Death or Grade 5 Impact on Creatinine0
Any Hyperglycaemia1
Mild or Grade 1 Hyperglycaemia1
Moderate or Grade 2 Hyperglycaemia0
Severe or Grade 3 Hyperglycaemia0
Potentially Life-Threatening or Grade 4 Hyperglycaemia0
Death or Grade 5 Hyperglycaemia0
SecondaryNumber of Participants Who Discontinue Treatment Due to ISRs and AESIs - SC Injection Phase
Time frame:
From Day 1 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to ISRs and AESIs - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Discontinuations due to ISR5
Discontinuations due to AESI0
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From the Last IM Gluteal Injection in Screening Phase to the End of the SC Injection Phase

SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs.

Time frame:
From Week -4 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From the Last IM Gluteal Injection in Screening Phase to the End of the SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Any AEs90
Any SAEs0
SecondaryChange From Baseline in Chemistry Parameters Following Administration of SC Injection: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Creatine Phosphokinase

Blood samples were collected as assessed by protocol, at specific time points for the analysis of clinical chemistry parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Creatine Phosphokinase
International units per liter (IU/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
ALT, Baseline (screening Week -4)21.6 ± 10.38
ALT, CFB at Week 41.2 ± 8.09
ALT, CFB at Week 8-0.4 ± 5.94
ALT, CFB at Week 12-0.7 ± 7.32
ALP, Baseline (screening Week -4)62.3 ± 14.72
ALP, CFB at Week 4-0.1 ± 7.51
ALP, CFB at Week 80.7 ± 6.66
ALP, CFB at Week 12-0.4 ± 6.29
AST, Baseline (screening Week -4)20.1 ± 6.27
AST, CFB at Week 42.2 ± 12.33
AST, CFB at Week 80.1 ± 5.52
AST, CFB at Week 12-0.2 ± 5.46
Creatine phosphokinase, Baseline (screening Week -4)166.8 ± 163.38
Creatine phosphokinase, CFB at Week 447.7 ± 340.57
Creatine phosphokinase, CFB at Week 83.3 ± 206.30
Creatine phosphokinase, CFB at Week 12-0.9 ± 162.90
SecondaryChange From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine, Total Bilirubin
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Micromoles per liter (umol/L)
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine, Total Bilirubin
Micromoles per liter (umol/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Creatinine, Baseline (screening Week -4)86.23 ± 14.551
Creatinine, CFB at Week 4-1.84 ± 5.811
Creatinine, CFB at Week 8-1.55 ± 8.224
Creatinine, CFB at Week 12-0.35 ± 7.206
Total Bilirubin, Baseline (screening Week -4)9.2 ± 4.01
Total Bilirubin, CFB at Week 40.5 ± 3.52
Total Bilirubin, CFB at Week 8-0.5 ± 3.64
Total Bilirubin, CFB at Week 12-1.2 ± 3.21
SecondaryChange From Baseline in Chemistry Parameters Following Administration of SC Injection: Glucose, Potassium, Sodium, Blood Urea Nitrogen, Carbon Dioxide, Chloride, Phosphate
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Glucose, Potassium, Sodium, Blood Urea Nitrogen, Carbon Dioxide, Chloride, Phosphate
Millimoles per liter (mmol/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Glucose, Baseline (screening Week -4)5.14 ± 0.808
Glucose, CFB at Week 12-0.02 ± 0.571
Potassium, Baseline (screening Week -4)4.19 ± 0.304
Potassium, CFB at Week 40.02 ± 0.389
Potassium, CFB at Week 80.03 ± 0.307
Potassium, CFB at Week 12-0.04 ± 0.346
Sodium, Baseline (screening Week -4)139.8 ± 1.81
Sodium, CFB at Week 4-0.1 ± 1.72
Sodium, CFB at Week 80.4 ± 2.11
Sodium, CFB at Week 120.3 ± 1.91
Blood Urea Nitrogen, Baseline (screening Week -4)5.33 ± 1.639
Blood Urea Nitrogen, CFB at Week 40.13 ± 1.206
Blood Urea Nitrogen, CFB at Week 80.22 ± 1.417
Blood Urea Nitrogen, CFB at Week 12-0.04 ± 1.368
Carbon Dioxide, Baseline (screening Week -4)23.6 ± 2.04
Carbon Dioxide, CFB at Week 4-0.3 ± 2.09
Carbon Dioxide, CFB at Week 8-0.6 ± 1.87
Carbon Dioxide, CFB at Week 12-0.5 ± 1.83
Chloride, Baseline (screening Week -4)103.7 ± 2.15
Chloride, CFB at Week 4-0.3 ± 2.55
Chloride, CFB at Week 80.6 ± 2.36
Chloride, CFB at Week 120.5 ± 2.38
Phosphate, Baseline (screening Week -4)1.103 ± 0.1651
Phosphate, CFB at Week 4-0.002 ± 0.1836
Phosphate, CFB at Week 80.023 ± 0.1731
Phosphate, CFB at Week 12-0.015 ± 0.1570
SecondaryChange From Baseline in Chemistry Parameter Following Administration of SC Injection: Albumin
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Chemistry Parameter Following Administration of SC Injection: Albumin
Grams per liter (g/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)43.1 ± 2.66
CFB at Week 40.4 ± 2.56
CFB at Week 80.8 ± 2.20
CFB at Week 12-0.1 ± 2.11
SecondaryChange From Baseline in Chemistry Parameters Following Administration of SC Injection: Lipase
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Lipase
Units per liter (U/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)29.4 ± 17.69
CFB at Week 40.3 ± 10.97
CFB at Week 85.6 ± 25.61
CFB at Week 121.4 ± 11.66
SecondaryChange From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine Clearance
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Milliliter per minute (mL/min)
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine Clearance
Milliliter per minute (mL/min)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)93.9 ± 15.15
CFB at Week 41.9 ± 6.95
CFB at Week 81.8 ± 9.37
CFB at Week 120.4 ± 8.06
SecondaryChange From Baseline in Fasting Lipid Panels Following Administration of SC Injection: Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Triglycerides
Time frame:
Baseline (screening Week -4), and CFB at Week 12
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Lipid Panels Following Administration of SC Injection: Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Triglycerides
mmol/LCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Total Cholesterol, Baseline (screening Week -4)4.855 ± 0.9604
Total Cholesterol, CFB at Week 12-0.073 ± 0.6056
HDL Cholesterol, Baseline (screening Week -4)1.373 ± 0.3764
HDL Cholesterol, CFB at Week 12-0.050 ± 0.1646
LDL Cholesterol, Baseline (screening Week -4)2.899 ± 0.8464
LDL Cholesterol, CFB at Week 12-0.040 ± 0.4786
Triglycerides, Baseline (screening Week -4)1.299 ± 0.8672
Triglycerides, CFB at Week 120.005 ± 0.5692
SecondaryChange From Baseline in Hematology Parameters Following Administration of SC Injection: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelet Count

Blood samples were collected as assessed by protocol, at specific time points for the analysis of hematology parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Giga cells per Liter (10^9 cells/L)
Change From Baseline in Hematology Parameters Following Administration of SC Injection: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelet Count
Giga cells per Liter (10^9 cells/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Basophils, Baseline (screening Week -4)0.048 ± 0.0264
Basophils, CFB at Week 40.000 ± 0.0274
Basophils, CFB at Week 8-0.003 ± 0.0309
Basophils, CFB at Week 12-0.002 ± 0.0343
Eosinophils, Baseline (screening Week -4)0.193 ± 0.1648
Eosinophils, CFB at Week 40.006 ± 0.1193
Eosinophils, CFB at Week 8-0.033 ± 0.0981
Eosinophils, CFB at Week 12-0.006 ± 0.1198
Leukocytes, Baseline (screening Week -4)6.12 ± 1.901
Leukocytes, CFB at Week 40.09 ± 1.524
Leukocytes, CFB at Week 8-0.24 ± 1.364
Leukocytes, CFB at Week 12-0.11 ± 1.210
Lymphocytes, Baseline (screening Week -4)2.076 ± 0.6398
Lymphocytes, CFB at Week 40.046 ± 0.4427
Lymphocytes, CFB at Week 8-0.066 ± 0.4864
Lymphocytes, CFB at Week 12-0.064 ± 0.4890
Monocytes, Baseline (screening Week -4)0.470 ± 0.1897
Monocytes, CFB at Week 4-0.006 ± 0.1204
Monocytes, CFB at Week 8-0.053 ± 0.1284
Monocytes, CFB at Week 12-0.044 ± 0.1448
Neutrophils, Baseline (screening Week -4)3.328 ± 1.3927
Neutrophils, CFB at Week 40.054 ± 1.3913
Neutrophils, CFB at Week 8-0.093 ± 1.0953
Neutrophils, CFB at Week 120.012 ± 0.9941
Platelet Count, Baseline (screening Week -4)256.2 ± 70.85
Platelet Count, CFB at Week 4-0.8 ± 33.28
Platelet Count, CFB at Week 8-3.5 ± 30.93
Platelet Count, CFB at Week 121.0 ± 36.35
SecondaryChange From Baseline in Hematology Parameter Following Administration of SC Injection: Red Blood Cell (RBC) Count
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Trillion cells per liter (10^12/L)
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Red Blood Cell (RBC) Count
Trillion cells per liter (10^12/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)4.74 ± 0.398
CFB at Week 40.03 ± 0.244
CFB at Week 80.01 ± 0.248
CFB at Week 12-0.04 ± 0.265
SecondaryChange From Baseline in Hematology Parameter Following Administration of SC Injection: Hemoglobin
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hemoglobin
Grams per liter (g/L)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)142.9 ± 12.14
CFB at Week 40.3 ± 7.02
CFB at Week 8-0.9 ± 6.87
CFB at Week 12-2.4 ± 7.43
SecondaryChange From Baseline in Hematology Parameter Following Administration of SC Injection: Hematocrit
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Proportion of red blood cells in blood (
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hematocrit
Proportion of red blood cells in blood (Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)0.4268 ± 0.03402
CFB at Week 40.0008 ± 0.02308
CFB at Week 80.0014 ± 0.02243
CFB at Week 12-0.0023 ± 0.02584
SecondaryChange From Baseline in Hematology Parameter Following Administration of SC Injection: Mean Corpuscular Volume
Time frame:
Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Reported as:
Mean · Femtoliters (fL)
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Mean Corpuscular Volume
Femtoliters (fL)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (screening Week -4)90.2 ± 4.49
CFB at Week 4-0.4 ± 1.74
CFB at Week 80.2 ± 2.04
CFB at Week 120.5 ± 2.51
SecondaryPercentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (c/mL) Using the Food and Drug Administration (FDA) Snapshot Algorithm - SC Injection Phase
Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (c/mL) Using the Food and Drug Administration (FDA) Snapshot Algorithm - SC Injection Phase
Percentage of participantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (Day 1)100 (96 to 100)
Week 4100 (96 to 100)
Week 899 (97 to 100)
Week 1290 (84 to 96)
SecondaryPercentage of Participants With Plasma HIV RNA Greater Than Equal to (>=) 50 c/mL as Per FDA Snapshot Algorithm - SC Injection Phase
Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV RNA Greater Than Equal to (>=) 50 c/mL as Per FDA Snapshot Algorithm - SC Injection Phase
Percentage of participantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Baseline (Day 1)0 (0.0 to 3.9)
Week 40 (0.0 to 4.0)
Week 81.1 (0.0 to 3.4)
Week 122.2 (0.0 to 5.1)
SecondaryPercentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase

Plasma samples were collected for quantitative analysis of HIV-1 RNA. CVF was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.

Time frame:
From Day 1 Up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase
Percentage of participantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase0
SecondaryNumber of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase

Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent phenotypic resistance were reported.

Time frame:
From Day 1 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Number of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase0
SecondaryNumber of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase

Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent genotypic resistance were reported.

Time frame:
From Day 1 Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Number of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase0
SecondaryNumber of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week-3 - Screening/IM Gluteal Injection Phase

A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Week -3 (Baseline)
Reported as:
Count of participants · Participants
Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week-3 - Screening/IM Gluteal Injection Phase
ParticipantsCAB Q4WRPV Q4W
Individual item score 03727
Individual item score 12116
Individual item score 21118
Individual item score 379
Individual item score 455
Individual item score 516
Individual item score 613
Individual item score 764
Individual item score 831
Individual item score 901
Individual item score 1002
SecondaryNumber of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week 1 - SC Injection Phase

A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week 1 - SC Injection Phase
ParticipantsCAB Q4WRPV Q4W
Individual Item Score 01622
Individual Item Score 11319
Individual Item Score 21610
Individual Item Score 3813
Individual Item Score 462
Individual Item Score 567
Individual Item Score 634
Individual Item Score 7107
Individual Item Score 865
Individual Item Score 972
Individual Item Score 1022
SecondaryNumber of Participants With Post-injection Pain Assessment Using NRS on Week 9- SC Injection Phase

A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Week 9
Reported as:
Count of participants · Participants
Number of Participants With Post-injection Pain Assessment Using NRS on Week 9- SC Injection Phase
ParticipantsCAB Q4WRPV Q4W
Individual Item Score 02119
Individual Item Score 1911
Individual Item Score 21915
Individual Item Score 3913
Individual Item Score 496
Individual Item Score 547
Individual Item Score 649
Individual Item Score 733
Individual Item Score 852
Individual Item Score 940
Individual Item Score 1002
SecondaryNumber of Participants With Post-injection Pain Assessment Using NRS on Week 13- Return to IM Gluteal Injection Phase

A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Week 13
Reported as:
Count of participants · Participants
Number of Participants With Post-injection Pain Assessment Using NRS on Week 13- Return to IM Gluteal Injection Phase
ParticipantsCAB Q4WRPV Q4W
Individual Item Score 04041
Individual Item Score 12113
Individual Item Score 21012
Individual Item Score 379
Individual Item Score 433
Individual Item Score 535
Individual Item Score 602
Individual Item Score 722
Individual Item Score 810
Individual Item Score 900
Individual Item Score 1000
SecondaryHIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase

HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

Time frame:
Week -3 (Baseline)
Reported as:
Mean · Scores on a scale
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase62.15 ± 5.258
SecondaryHIVTSQs Total Score -SC Injection Phase

HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

Time frame:
At Week 9
Reported as:
Mean · Scores on a scale
HIVTSQs Total Score -SC Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
HIVTSQs Total Score -SC Injection Phase51.99 ± 14.765
SecondaryHIVTSQs Total Score -Return to IM Gluteal Injection Phase

HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.

Time frame:
At Week 17
Reported as:
Mean · Scores on a scale
HIVTSQs Total Score -Return to IM Gluteal Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
HIVTSQs Total Score -Return to IM Gluteal Injection Phase62.71 ± 4.217
SecondaryChange From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points -SC Injection Phase

HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

Time frame:
Baseline (Week -3) and up to Week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points -SC Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Item 1-1.2 ± 1.85
Item 2-0.2 ± 0.79
Item 3-1.5 ± 1.93
Item 4-1.1 ± 1.67
Item 5-1.2 ± 1.88
Item 6-0.8 ± 1.83
Item 7-0.2 ± 0.93
Item 8-0.8 ± 1.59
Item 9-1.1 ± 1.68
Item 10-1.4 ± 1.97
Item 11-1.0 ± 1.47
Item 12-1.3 ± 1.79
SecondaryChange From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

Time frame:
Baseline (Week -3) and up to Week 17
Reported as:
Mean · Scores on a scale
Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Item 10.1 ± 0.43
Item 2-0.1 ± 0.35
Item 30.1 ± 0.72
Item 40.0 ± 0.63
Item 50.0 ± 0.55
Item 60.0 ± 0.95
Item 70.1 ± 0.55
Item 80.0 ± 0.55
Item 90.0 ± 0.32
Item 100.1 ± 0.57
Item 110.0 ± 0.58
Item 120.2 ± 0.79
SecondaryChange From Study Week 9 to Study Week 17 in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.

Time frame:
Week 9 and Week 17
Reported as:
Mean · Scores on a scale
Change From Study Week 9 to Study Week 17 in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Item 11.3 ± 1.77
Item 20.2 ± 0.77
Item 31.6 ± 1.85
Item 41.1 ± 1.60
Item 51.2 ± 1.78
Item 60.8 ± 1.41
Item 70.2 ± 0.83
Item 80.8 ± 1.40
Item 91.0 ± 1.68
Item 101.5 ± 1.97
Item 111.0 ± 1.39
Item 121.5 ± 1.88
SecondaryHIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Individual Item Score at Indicated Time Points -SC Injection Phase

HIVTSQc is a 12-item questionnaire to measure treatment satisfaction in HIV participants. Individual items were rated as +3 (much more satisfied) to -3(much less satisfied). Higher the score, greater the improvement in satisfaction with each aspect of treatment and lower the score, greater the deterioration in satisfaction with each aspect of treatment. Data was reported for each treatment satisfaction item based on the following items:Item 1=satisfaction with current treatment,Item2=level of HIV control based on treatment,Item3=any side effects of present treatment,Item4=demands made by current treatment,Item 5=convenience in finding treatment,Item 6=flexibility in finding treatment,Item 7=understanding HIV,Item 8=extent to which the treatment fits in with lifestyle,Item 9=recommendation of present treatment to someone else,Item 10=continuation with present form of treatment,Item 11=easy or difficult treatment,Item 12=amount of discomfort/pain involved with present form of treatment.

Time frame:
From Week -4 up to Week 9
Reported as:
Mean · Scores on a scale
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Individual Item Score at Indicated Time Points -SC Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Item 10.7 ± 2.14
Item 21.8 ± 1.40
Item 30.5 ± 2.04
Item 41.2 ± 1.75
Item 51.0 ± 2.06
Item 61.3 ± 1.76
Item 72.0 ± 1.32
Item 81.4 ± 1.77
Item 91.3 ± 1.92
Item 100.9 ± 2.11
Item 111.2 ± 1.77
Item 120.5 ± 2.18
SecondaryHIVTSQc Total Score at Indicated Time Points -SC Injection Phase

HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.

Time frame:
From Week -4 up to Week 9
Reported as:
Mean · Scores on a scale
HIVTSQc Total Score at Indicated Time Points -SC Injection Phase
Scores on a scaleCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
HIVTSQc Total Score at Indicated Time Points -SC Injection Phase13.4 ± 17.79
SecondaryPerception of Injection (PIN) Questionnaire in Domain Scores and Individual Item Scores- Screening/IM Gluteal Injection Phase

The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
At Week -3 (Baseline)
Reported as:
Mean · Scores on a scale
Perception of Injection (PIN) Questionnaire in Domain Scores and Individual Item Scores- Screening/IM Gluteal Injection Phase
Scores on a scaleCAB Q4WRPV Q4W
Bother of ISRs1.44 ± 0.4841.53 ± 0.568
Acceptance1.51 ± 0.6761.71 ± 0.781
SecondaryPIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase

The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
At Week 1 and Week 9
Reported as:
Mean · Scores on a scale
PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase
Scores on a scaleCAB Q4WRPV Q4W
Bother of ISRs, Week 12.23 ± 0.9181.95 ± 0.913
Bother of ISRs, Week 92.10 ± 0.9641.93 ± 0.891
Acceptance, Week 12.60 ± 1.1732.28 ± 1.167
Acceptance, Week 92.30 ± 1.2062.12 ± 1.156
SecondaryPIN Questionnaire in Domain Scores and Individual Item Scores - Return to IM Gluteal Injection Phase

The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
At Week 13
Reported as:
Mean · Scores on a scale
PIN Questionnaire in Domain Scores and Individual Item Scores - Return to IM Gluteal Injection Phase
Scores on a scaleCAB Q4WRPV Q4W
Bother of ISRs1.23 ± 0.3581.28 ± 0.377
Acceptance1.32 ± 0.5701.46 ± 0.679
SecondaryChange From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase

The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Change from Baseline (Week -3) at Week 1 and Week 9
Reported as:
Mean · Scores on a scale
Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase
Scores on a scaleCAB Q4WRPV Q4W
Bother of ISRs, Change from Baseline at Week 10.79 ± 0.8430.41 ± 0.909
Bother of ISRs, Change from Baseline at Week 90.70 ± 0.9310.41 ± 0.877
Acceptance, Change from Baseline at Week 11.09 ± 1.1000.58 ± 1.177
Acceptance, Change from Baseline at Week 90.86 ± 1.1450.44 ± 1.103
SecondaryChange From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase

The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).

Time frame:
Change from Baseline (Week -3) at Week 13
Reported as:
Mean · Scores on a scale
Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
Scores on a scaleCAB Q4WRPV Q4W
Bother of ISRs-0.17 ± 0.369-0.24 ± 0.537
Acceptance-0.12 ± 0.719-0.22 ± 0.888
SecondaryNumber of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 9 - SC Injection Phase

A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.

Time frame:
Up to Week 9
Reported as:
Count of participants · Participants
Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 9 - SC Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Intramuscular Injections in the buttock50
Subcutaneous Injections in the Abdomen29
No preference6
SecondaryNumber of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 17 - Return to IM Gluteal Injection Phase

A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.

Time frame:
Up to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 17 - Return to IM Gluteal Injection Phase
ParticipantsCabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Intramuscular Injections in the buttock61
Subcutaneous Injections in the Abdomen21
No preference5

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected from Week -4 for screening/Gluteal injection phase, from day 1 up to 12 weeks for SC Injection Phase and from Week 12 to Week 20 for Return to IM Gluteal Injection Phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB LA 400 mg + RPV LA 600 mg - Screening Phase1/94 (1.1%)1/94 (1.1%)33/94 (35.1%)
CAB LA 400 mg + RPV LA 600 mg - SC Injection Phase0/93 (0%)0/93 (0%)85/93 (91.4%)
CAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase0/93 (0%)0/93 (0%)38/93 (40.9%)
Most frequent serious events
Most frequent serious events
EventCAB LA 400 mg + RPV LA 600 mg - Screening PhaseCAB LA 400 mg + RPV LA 600 mg - SC Injection PhaseCAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase
Passed away due to unknown reasonsGeneral disorders1/940/930/93
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCAB LA 400 mg + RPV LA 600 mg - Screening PhaseCAB LA 400 mg + RPV LA 600 mg - SC Injection PhaseCAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase
Injection site painGeneral disorders29/9469/9330/93
Injection site noduleGeneral disorders3/9460/939/93
Injection site erythemaGeneral disorders0/9448/931/93
Injection site swellingGeneral disorders0/9429/931/93
Injection site indurationGeneral disorders0/9424/932/93
Injection site pruritusGeneral disorders2/9419/931/93
Injection site warmthGeneral disorders0/9411/930/93
Injection site haematomaGeneral disorders0/947/931/93
Injection site bruisingGeneral disorders0/946/931/93
Injection site discolourationGeneral disorders0/946/930/93

Baseline characteristics

Baseline characteristics presented based on sub-study Safety population. Summary of baseline/demographics for some race/ ethnicity variables are presented as de-identified to prevent risk of participant re-identification.

Age, Continuous
Age, Continuous(Years)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Mean42.8 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Female18
Male75
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg
Black or African American19
White - White/Caucasian/European Heritage63
De-identified11
08

Study locations

30 sites
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Bloemfontein, Free State 9301, South Africa
  • GSK Investigational Site
    Wentworth, KwaZulu- Natal 4052, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Bilbao, 48013, Spain
  • GSK Investigational Site
    Elche, 03203, Spain
  • GSK Investigational Site
    Ferrol, 15405, Spain
  • GSK Investigational Site
    Granada, 18016, Spain
  • GSK Investigational Site
    La Laguna-Tenerife, 38320, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Murcia, 30003, Spain
  • GSK Investigational Site
    Murcia, 30120, Spain
  • GSK Investigational Site
    Palma De Mallorca, 07198, Spain
  • GSK Investigational Site
    San Sebastian de los Reyes, 28702, Spain
  • GSK Investigational Site
    Santa Cruz de Tenerife, 38010, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • GSK Investigational Site
    Leeds, LS1 3EX, United Kingdom
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Sep 2023, 10 months.

Results were first posted in Nov 2024, 1 year 2 months after primary completion.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 10 months is below that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
Nov 8, 2022
Primary completionActual
Sep 14, 2023
CompletionActual
Sep 14, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05896748
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Nov 8, 2022
Primary completion
Sep 14, 2023
Completion
Sep 14, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabotegravir · Rilpivirine

Start the discussion